
Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia
The commercial availability of an AB-rated generic formulation of eltrombopag (Promacta) represents a meaningful development that could help expand access to treatment for patients with immune thrombocytopenia (ITP) and severe aplastic anemia, according to …